NCT00064493

Brief Summary

To identify genetic variation in reverse cholesterol transport (RCT) and its role in cardiovascular disease and atherosclerosis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,146

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2003

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2003

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 8, 2003

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 10, 2003

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2008

Completed
Last Updated

October 1, 2021

Status Verified

September 1, 2021

Enrollment Period

4.9 years

First QC Date

July 8, 2003

Last Update Submit

September 29, 2021

Conditions

Cardiovascular DiseasesHeart DiseasesAtherosclerosis

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The sample to be studied by this Collaborative Research Project Grants consists of 2007 African-Americans and 2139 European-Americans equally divided between males and females between 18-30 years of age at the time of entry into the Coronary Artery Risk Development in Young Adults (CARDIA) study in 1985.

No eligibility criteria

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (2)

  • Hamon SC, Stengard JH, Clark AG, Salomaa V, Boerwinkle E, Sing CF. Evidence for non-additive influence of single nucleotide polymorphisms within the apolipoprotein E gene. Ann Hum Genet. 2004 Nov;68(Pt 6):521-35. doi: 10.1046/j.1529-8817.2003.00112.x.

    PMID: 15598211BACKGROUND

  • Klos KL, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res. 2005 Mar;46(3):564-71. doi: 10.1194/jlr.M400437-JLR200. Epub 2004 Dec 16.

    PMID: 15604515BACKGROUND

MeSH Terms

Conditions

Cardiovascular DiseasesHeart DiseasesAtherosclerosis

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Eric Boerwinkle

    University of Texas School of Public Health

    PRINCIPAL INVESTIGATOR

  • Andrew Clark

    Cornell University

    PRINCIPAL INVESTIGATOR

  • Charles Sing

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor - School of Public Health

Study Record Dates

First Submitted

July 8, 2003

First Posted

July 10, 2003

Study Start

June 1, 2003

Primary Completion

May 1, 2008

Study Completion

May 1, 2008

Last Updated

October 1, 2021

Record last verified: 2021-09